Anavex Life Sciences (AVXL) Leaps on FDA Nod

Anavex Life Sciences Corp.

rose 11.8% to $5.95 as the company reported that it has received the FDA approval for Orphan Drug Designation for Frontotemporal dementia treatment. Share volume was 796,000, compared to an all-day average of 188,000